Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

A Fragment of Apolipoprotein E4 Leads to the Downregulation of a CXorf56 Homologue, a Novel ER-Associated Protein, and Activation of BV2 Microglial Cells.

Pollock TB, Mack JM, Day RJ, Isho NF, Brown RJ, Oxford AE, Morrison BE, Hayden EJ, Rohn TT.

Oxid Med Cell Longev. 2019 May 6;2019:5123565. doi: 10.1155/2019/5123565. eCollection 2019.

2.

Contributions of VPS35 Mutations to Parkinson's Disease.

Rahman AA, Morrison BE.

Neuroscience. 2019 Mar 1;401:1-10. doi: 10.1016/j.neuroscience.2019.01.006. Epub 2019 Jan 18. Review.

3.

Nigral dopaminergic neuron replenishment in adult mice through VE-cadherin-expressing neural progenitor cells.

Rahman AA, Lai NK, Albright JE, Urquhart PE, Webb AR, Morrison BE.

Neural Regen Res. 2017 Nov;12(11):1865-1869. doi: 10.4103/1673-5374.219050.

4.

Nuclear uptake of an amino-terminal fragment of apolipoprotein E4 promotes cell death and localizes within microglia of the Alzheimer's disease brain.

Love JE, Day RJ, Gause JW, Brown RJ, Pu X, Theis DI, Caraway CA, Poon WW, Rahman AA, Morrison BE, Rohn TT.

Int J Physiol Pathophysiol Pharmacol. 2017 Apr 15;9(2):40-57. eCollection 2017.

5.

Discovery of nigral dopaminergic neurogenesis in adult mice.

Morrison BE.

Neural Regen Res. 2016 Jun;11(6):878-81. doi: 10.4103/1673-5374.184449. Review.

6.

Nestin-positive/SOX2-negative cells mediate adult neurogenesis of nigral dopaminergic neurons in mice.

Albright JE, Stojkovska I, Rahman AA, Brown CJ, Morrison BE.

Neurosci Lett. 2016 Feb 26;615:50-4. doi: 10.1016/j.neulet.2016.01.019. Epub 2016 Jan 20.

7.

Parkinson's disease and enhanced inflammatory response.

Stojkovska I, Wagner BM, Morrison BE.

Exp Biol Med (Maywood). 2015 Nov;240(11):1387-95. doi: 10.1177/1535370215576313. Epub 2015 Mar 13. Review.

8.

Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Eschbach J, von Einem B, Müller K, Bayer H, Scheffold A, Morrison BE, Rudolph KL, Thal DR, Witting A, Weydt P, Otto M, Fauler M, Liss B, McLean PJ, Spada AR, Ludolph AC, Weishaupt JH, Danzer KM.

Ann Neurol. 2015 Jan;77(1):15-32. doi: 10.1002/ana.24294. Epub 2014 Dec 19.

9.

Let-7 coordinately suppresses components of the amino acid sensing pathway to repress mTORC1 and induce autophagy.

Dubinsky AN, Dastidar SG, Hsu CL, Zahra R, Djakovic SN, Duarte S, Esau CC, Spencer B, Ashe TD, Fischer KM, MacKenna DA, Sopher BL, Masliah E, Gaasterland T, Chau BN, Pereira de Almeida L, Morrison BE, La Spada AR.

Cell Metab. 2014 Oct 7;20(4):626-38. doi: 10.1016/j.cmet.2014.09.001.

10.

Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide.

Morrison BE, Marcondes MC, Nomura DK, Sanchez-Alavez M, Sanchez-Gonzalez A, Saar I, Kim KS, Bartfai T, Maher P, Sugama S, Conti B.

J Immunol. 2012 Dec 15;189(12):5498-502. doi: 10.4049/jimmunol.1102150. Epub 2012 Nov 19.

11.

PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.

Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, Lazarowski ER, Damian VA, Masliah E, La Spada AR.

Sci Transl Med. 2012 Jul 11;4(142):142ra97. doi: 10.1126/scitranslmed.3003799.

12.

Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation.

Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF.

Science. 2011 Nov 11;334(6057):809-13. doi: 10.1126/science.1209200. Epub 2011 Oct 20.

13.

Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity.

Pfister JA, Ma C, Morrison BE, D'Mello SR.

PLoS One. 2008;3(12):e4090. doi: 10.1371/journal.pone.0004090. Epub 2008 Dec 31.

14.

HDAC4 inhibits cell-cycle progression and protects neurons from cell death.

Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR.

Dev Neurobiol. 2008 Jul;68(8):1076-92. doi: 10.1002/dneu.20637.

15.

Polydactyly in mice lacking HDAC9/HDRP.

Morrison BE, D'Mello SR.

Exp Biol Med (Maywood). 2008 Aug;233(8):980-8. doi: 10.3181/0802-RM-48. Epub 2008 May 14.

16.

Class IIA HDACs in the regulation of neurodegeneration.

Majdzadeh N, Morrison BE, D'Mello SR.

Front Biosci. 2008 Jan 1;13:1072-82. Review.

17.

Histone deacetylases: focus on the nervous system.

Morrison BE, Majdzadeh N, D'Mello SR.

Cell Mol Life Sci. 2007 Sep;64(17):2258-69. Review.

PMID:
17530170
18.

Neuroprotection by histone deacetylase-related protein.

Morrison BE, Majdzadeh N, Zhang X, Lyles A, Bassel-Duby R, Olson EN, D'Mello SR.

Mol Cell Biol. 2006 May;26(9):3550-64.

19.

The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism.

Chin PC, Liu L, Morrison BE, Siddiq A, Ratan RR, Bottiglieri T, D'Mello SR.

J Neurochem. 2004 Aug;90(3):595-608.

20.

Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis.

Morrison BE, Park SJ, Mooney JM, Mehrad B.

J Clin Invest. 2003 Dec;112(12):1862-70.

21.

Transient lung-specific expression of the chemokine KC improves outcome in invasive aspergillosis.

Mehrad B, Wiekowski M, Morrison BE, Chen SC, Coronel EC, Manfra DJ, Lira SA.

Am J Respir Crit Care Med. 2002 Nov 1;166(9):1263-8.

PMID:
12403697
22.

Disposition and pharmacokinetics of naltrexone after intravenous and oral administration in rhesus monkeys.

Reuning RH, Ashcraft SB, Wiley JN, Morrison BE.

Drug Metab Dispos. 1989 Nov-Dec;17(6):583-9.

PMID:
2575491
23.

Formation of [20R]-dihydrodigoxin from digoxin in humans.

Reuning RH, Shepard TA, Morrison BE, Bockbrader HN.

Drug Metab Dispos. 1985 Jan-Feb;13(1):51-7.

PMID:
2858377
24.

An electron-capture gas chromatographic assay for naltrexone in biological fluids.

Reuning RH, Ashcraft SB, Morrison BE.

NIDA Res Monogr. 1981;28:25-35.

PMID:
6791008
25.

Plasma naltrexone kinetics after intravenous bolus administration in dogs and monkeys.

Reuning RH, Batra VK, Ludden TM, Jao MY, Morrison BE, McCarthy DA, Harrigan SE, Ashcraft SB, Sams RA, Bathala MS, Staubus AE, Malspeis L.

J Pharm Sci. 1979 Apr;68(4):411-6.

PMID:
108382
26.

Metabolic reduction of naltrexone II. In vitro studies using liver from guinea pig, monkey and rat.

Malspeis L, Ludden TM, Bathala MS, Morrison BE, Feller DR, Reuning RH.

Res Commun Chem Pathol Pharmacol. 1976 Jul;14(3):393-406.

PMID:
822483
27.

Supplemental Content

Loading ...
Support Center